Capricor Therapeutics Announces Long-Term Benefit Of Deramiocel In Both Skeletal Muscle And Cardiac Function In The HOPE-2 OLE Study In Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. CAPR | 21.46 21.46 | -1.47% 0.00% Pre |
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients-
-Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment-
-Pre-BLA Meeting with FDA Scheduled for Q3 2024 to Discuss Options to Expedite BLA Filing-
-Results to be Presented at PPMD Annual Conference on June 29 in Session titled "Approaches to Alter Progression"-
SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset, deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy (DMD).